Role of betaine in improving the antidepressant effect of S-adenosyl-methionine in patients with mild-to-moderate depression

Journal of Multidisciplinary Healthcare

Volumn 8, Issue , 2015, Pages 39-45

  Di Pierro, Francesco ^a   Orsi, Rossana ^b   Settembre, Roberto ^c  

^a Scientific Department   (Italy)

^b ASL TO1   (Italy)

^c DI VENERE HOSPITAL   (Italy)

Author keywords

Betaine; DDM Metile ; Methyl donor; Mild to moderate depression; SAMe; Samyr

Indexed keywords

ALPRAZOLAM; AMFEBUTAMONE; BETAINE; BETAINE PLUS S ADENOSYLMETHIONINE; BROMAZEPAM; CITALOPRAM; DULOXETINE; ESCITALOPRAM; ETIZOLAM; MIRTAZAPINE; PAROXETINE; S ADENOSYLMETHIONINE; SERTRALINE; TRAZODONE; UNCLASSIFIED DRUG;

ADD ON THERAPY; ADULT; AGED; ANTIDEPRESSANT ACTIVITY; ANXIETY; ARTICLE; BECK DEPRESSION INVENTORY; BURNING SENSATION; CLINICAL ARTICLE; CONTROLLED STUDY; DEPRESSION; DISEASE CONTROL; DISEASE SEVERITY; DRUG POTENTIATION; DRUG TOLERABILITY; FEMALE; HELPLESSNESS; HUMAN; MALE; MOUTH BURNING SENSATION; OBSERVATIONAL STUDY; PATIENT COMPLIANCE; RANDOMIZED CONTROLLED TRIAL; RESTLESSNESS; SOMATIZATION; SYMPTOM;

EID: 84921769185     PISSN: None     EISSN: 11782390     Source Type: Journal    
DOI: 10.2147/JMDH.S77766     Document Type: Article

References (21)

1. Hardy ML, Coulter I, Morton SC, et al. S-adenosyl-L-methionine for treatment of depression, osteoarthritis, and liver disease. Evid Rep Technol Assess (Summ). 2003;64:1–3.
2. Mischoulon D, Price LH, Carpenter LL, et al. A double-blind, randomized, placebo-controlled clinical trial of S-adenosyl-L-methionine (SAMe) versus escitalopram in major depressive disorder. J Clin Psychiatry. 2014;75(4):370–376.
3. Sarris J, Papakostas GI, Vitolo O, Fava M, Mischoulon D. S-adenosyl methionine (SAMe) versus escitalopram and placebo in major depression RCT: effcacy and effects of histamine and carnitine as moderators of response. J Affect Disord. 2014;164:76–81.
4. Spillmann M, Fava M. S-adenosyl-methionine (ademethionine) in psychiatric disorders. CNS Drugs. 1996;6:416–425.
5. Alpert JE, Mischoulon D. One-carbon metabolism and the treatment of depression: roles of S-adenosyl methionine (SAMe) and folic acid. In: Mischoulon D, Rosenbaum J, editors. Natural Medications for Psychiatric Disorders: Considering the Alternatives. Philadelphia: Lippincott Williams & Wilkins; 2002:44.
6. Bertoia ML, Pai JK, Cooke J P, et al. Plasma homocysteine, dietary B vitamins, betaine, and choline and risk of peripheral artery disease. Atherosclerosis. 2014;235(1):94–101.
7. Permoda-Osip A, Dorszewska J, Skibinska M, Chlopocka-Wozniak M, Rybakowski JK. Hyperhomocysteinemia in bipolar depression: clinical and biochemical correlates. Neuropsychobiology. 2013;68(4): 193–196.
8. Narayan SK, Verman A, Kattimani S, Ananthanarayanan PH, Adithan C. Plasma homocysteine levels in depression and schizophrenia in South Indian Tamilian population. Indian J Psychiatry. 2014;56(1):46–53.
9. Owen RT. Folate augmentation of antidepressant response. Drugs Today (Barc). 2013;49(12):791–798.
10. Erbe S, Pellert UN. Folates in the treatment of depression. Fortschr Neurol Psychiatr. 2014;82(2):78–83.
11. Kharbanda KK, Rogers DD 2nd, Mailliard ME, et al. A comparison of the effects of betaine and S-adenosylmethionine on ethanol-induced changes in methionine metabolism and steatosis in rat hepatocytes. J Nutr. 2005;135(3):519–524.
12. Knopman D, Patterson M. An open-label, 24-week pilot study of the methyl donor betaine in Alzheimer disease patients. Alzheimer Dis Assoc Disord. 2001;15(3):162–165.
13. World Medical Association. World medical association declaration of Helsinki: ethical principles for medical research involving human subjects. J Postgrad Med. 2002;48(3):206–208.
14. Richter P, Werner J, Heerlein A, Kraus A, Sauer H. On the validity of the Beck depression inventory. A review. Psychopathology. 1 998;31(3): 160–168.
15. Huskisson EC, Jones J, Scott PJ. Application of visual-analogue scales to the measurement of functional capacity. Rheumatol Rehabil. 1976;15(3):185–187.
16. Levkovitz Y, Alpert JE, Brintz CE, Mischoulon D, Papakostas GI. Effects of S-adenosylmethionine augmentation of serotonin-reuptake inhibitor antidepressants on cognitive symptoms of major depressive disorder. J Affect Disord. 2012;136(3):1174–1178.
17. Abularrage CJ, Sidawy AN, White P W, et al. Effect of folic acid and vitamins B6 and B12 on microcirculatory vasoreactivity in patients with hyperhomocysteinemia. Vasc Endovascular Surg. 2007;41(4): 339–345.
18. Olthof MR, Verhoef P. Effects of betaine intake on plasma homo-cysteine concentrations and consequences for health. Curr Drug Metab. 2005;6(1):15–22.
19. Schwab U, Törrönen A, Meririnne E, et al. Orally administered betaine has an acute and dose-dependent effect on serum betaine and plasma homocysteine concentrations in healthy humans. J Nutr. 2006;136(1): 34–38.
20. Olthof MR, van Vliet T, Boelsma E, Verhoef P. Low dose betaine supplementation leads to immediate and long term lowering of plasma homocysteine in healthy men and women. J Nutr. 2003;133(12): 4135–4138.
21. Mischoulon D, Alpert JE, Arning E, Bottiglieri T, Fava M, Papakostas GI. Bioavailability of S-adenosyl methionine and impact on response in a randomized, double-blind, placebo-controlled trial in major depressive disorder. J Clin Psychiatry. 2012;73(6):843–848.